{"id":359214,"date":"2019-04-23T14:10:03","date_gmt":"2019-04-23T14:10:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=359214"},"modified":"2019-04-23T14:10:03","modified_gmt":"2019-04-23T14:10:03","slug":"creative-biolabs-updates-antibody-design-and-conjugation-services","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-updates-antibody-design-and-conjugation-services_359214.html","title":{"rendered":"Creative Biolabs Updates Antibody Design and Conjugation Services"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>New York, April 23, 2019<\/strong> As a rich-experienced antibody company engaged in antibody-drug conjugates (ADC) fields, Creative Biolabs recently updated the <a rel=\"nofollow\" href=\"https:\/\/www.creative-biolabs.com\/adc\/antibody-design-and-conjugation.htm\">antibody design<\/a> and conjugation service to better satisfy the different needs of global clients.<\/p>\n<p style=\"text-align: justify;\">Antibody-drug conjugates refer to complex molecules composed of a monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components.&nbsp; It is a novel therapeutic application to combine the antitumor activity of antibodies with the killing effects of some chemical drugs. A high-quality ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.<\/p>\n<p style=\"text-align: justify;\">The ADC design is a complicated process that involves careful planning, meticulous execution, and intensive trouble-shooting, requiring a professional platform, rich reserve of knowledge and expert skills. Scientists at Creative Biolabs are experienced in performing <a rel=\"nofollow\" href=\"https:\/\/www.creative-biolabs.com\/adc\/antibody-drug-conjugate-adc.htm\">antibody conjugation<\/a> service including Lysine conjugation (amine reaction), Cysteine conjugation (thiol reactions) and Tyrosine conjugation to create ADCs using endogenous amino acids.<\/p>\n<p style=\"text-align: justify;\">To reduce the heavily dispersed drug-to-antibody ratio (DAR) caused by the non-uniform distribution of the conjugation sites when using endogenous amino acids, Creative Biolabs has explored and updated a variety of methodologies in antibody design and engineering to introduce a series of specific and chemically versatile conjugation sites into the antibody sequences:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Incorporating Cysteine residues into defined sites on an antibody to create thiol-engineered antibody (EnCys-mAb) and conjugate payload drugs onto those Cysteine residues via thiol-based chemistry.<\/li>\n<li>Integrating unnatural amino acids (UAAs), such as p-Acetyl Phenylalanine into antibody sequences via amber stop codon-mediated transcription<\/li>\n<li>Developing enzyme-mediated modification and conjugation system to help generate ADCs with specific conjugation sites.<\/li>\n<li>Creating a &ldquo;cave&rdquo; on the desired locations on an antibody to facilitate meditope trapping and subsequently, achieving site-specific meditope-based conjugations.<\/li>\n<li>Utilizing the self-splicing inteins and engineer intein-fusion antibodies, thereby achieving C-terminal specific antibody modification and yielding <a rel=\"nofollow\" href=\"https:\/\/www.creative-biolabs.com\/adc\/antibody-design-and-conjugation.htm\">conjugation DAR<\/a> at 1 or 2.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;Alongside the efforts of antibody engineering, we also apply several enzymatic or physical approaches to affording site-specific antibody-drug conjugations by modifying the carbohydrate moiety via galactosidases and galactosyltransferases or photo-crosslinking indole-3-butyric acid containing linkers onto antibody nucleotide binding site.&rdquo; Added a scientist in Creative Biolabs.<\/p>\n<p style=\"text-align: justify;\">Advanced antibody design platform and services from Creative Biolabs will become the best companion in creating a chemically compatible antibody for the conjugation chemistry. &nbsp;More detailed information can be found at <a rel=\"nofollow\" href=\"https:\/\/www.creative-biolabs.com\/adc\/\">https:\/\/www.creative-biolabs.com\/adc\/<\/a>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">About<\/p>\n<p style=\"text-align: justify;\">With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production\/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/creative-biolabs.com_17005.html\" rel=\"nofollow\">Creative Biolabs<\/a><br \/><strong>Contact Person:<\/strong> Candy Swift<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=creative-biolabs-updates-antibody-design-and-conjugation-services\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 1-631-619-7922<br \/><strong>Address:<\/strong>45-1 Ramsey Road  <br \/><strong>City:<\/strong> Shirley<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.creative-biolabs.com\/adc\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.creative-biolabs.com\/adc\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=creative-biolabs-updates-antibody-design-and-conjugation-services\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New York, April 23, 2019 As a rich-experienced antibody company engaged in antibody-drug conjugates (ADC) fields, Creative Biolabs recently updated the antibody design and conjugation service to better satisfy the different needs of global clients. Antibody-drug conjugates refer to complex &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-updates-antibody-design-and-conjugation-services_359214.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-359214","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/359214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=359214"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/359214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=359214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=359214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=359214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}